巴曲酶治疗椎-基底动脉短暂性脑缺血发作的临床分析

Clinical Observation of Batroxobin in the Treatment of Vertebro-basilar Artery transient ischemic attack

目的观察巴曲酶治疗椎-基底动脉短暂性脑缺血发作(VBI)的临床疗效,探讨其机制。方法将50例VBI患者随机分成常规治疗组(盐酸培他啶氯化钠注射液+川芎嗪注射液)和巴曲酶治疗组,观察治疗14d后临床疗效及入院时与治疗3d后纤维蛋白原含量的变化情况。结果巴曲酶治疗组与常规治疗组比较疗效更佳,其治疗前后临床症状、纤维蛋白原含量有显著差异。结论巴曲酶促使纤维蛋白原降解,阻止血栓进一步形成,能有效治疗因微栓塞所致的VBI。

Objective To investigate the clinical effect of Batroxobin in the treatment of vertebro - basilar transient is- chemic attack （VBI） and to explore the mechanism. Methods 50 VBI patients were divided into routine treatment group （Beathistine injection plus Tetramethylpyrazine injection） mad Batroxobin group randomly. Clinical effect post 14d treatment and the changes of fibrin content when admission and after 3d treatment. Results Batroxobin group has better effect than routine treatment group, the syndrome and the fibrin content have obviously difference. Conclusion Batrox- obin can promote fibrinogen degradation and prevent thromb formation, so that could effective treat VBI induced by microembolization.